Drug intelligence / Profile preview

HIP-2001

Development stage: Unknown
Lead developer: Hanmi Pharmaceutical

Overview

HIP-2001 is an investigational drug developed by Hanmi Pharmaceutical for the treatment of cardiovascular diseases, with a primary focus on atrial fibrillation. The precise mechanism of action and molecular target for HIP-2001 have not been disclosed publicly. The drug has undergone Phase 1 clinical trials to evaluate its pharmacokinetic characteristics and safety in healthy volunteers. As of the latest updates, there are no known adverse events or FDA designations associated with this compound[1][2]. Its development status remains pending beyond Phase 1.

Beyond the preview

Go deeper on HIP-2001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HIP-2001.

Explore the full profile